Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Long-Term Investments (2016 - 2024)

Marimed (MRMD) has disclosed Long-Term Investments for 10 consecutive years, with $274000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Long-Term Investments changed N/A to $274000.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $274000.0, a N/A change, with the full-year FY2023 number at $221000.0, changed N/A from a year prior.
  • Long-Term Investments was $274000.0 for Q1 2024 at Marimed, up from $221000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $2.5 million in Q4 2020 to a low of $89000.0 in Q2 2023.
  • A 5-year average of $1.1 million and a median of $419803.0 in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 90.46% in 2020, then tumbled 95.96% in 2022.
  • Marimed's Long-Term Investments stood at $2.5 million in 2020, then plummeted by 90.05% to $251000.0 in 2021, then crashed by 60.16% to $100000.0 in 2022, then skyrocketed by 121.0% to $221000.0 in 2023, then rose by 23.98% to $274000.0 in 2024.
  • Per Business Quant, the three most recent readings for MRMD's Long-Term Investments are $274000.0 (Q1 2024), $221000.0 (Q4 2023), and $164000.0 (Q3 2023).